Chemed (CHE) Updates FY18 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY18 earnings guidance on Wednesday morning. The company provided earnings per share guidance of $10.60-10.85 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.01.

Shares of Chemed (NYSE CHE) traded up $4.35 during mid-day trading on Wednesday, reaching $253.73. 140,231 shares of the company’s stock traded hands, compared to its average volume of 97,507. The company has a current ratio of 0.50, a quick ratio of 0.48 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $4,033.49, a price-to-earnings ratio of 56.38 and a beta of 1.13. Chemed has a one year low of $170.54 and a one year high of $275.83.

CHE has been the subject of several research analyst reports. KeyCorp reaffirmed a hold rating on shares of Chemed in a research note on Friday, October 27th. Oppenheimer raised their price objective on shares of Chemed from $220.00 to $225.00 and gave the company an outperform rating in a research note on Friday, October 27th. TheStreet raised shares of Chemed from a c+ rating to an a- rating in a research note on Friday, October 27th. Royal Bank of Canada raised their price objective on shares of Chemed to $232.00 and gave the company a sector perform rating in a research note on Tuesday, October 31st. Finally, Zacks Investment Research raised shares of Chemed from a hold rating to a buy rating and set a $251.00 price objective for the company in a research note on Thursday, November 2nd. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The company has an average rating of Hold and a consensus price target of $236.00.

In other news, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $238.24, for a total value of $238,240.00. Following the completion of the transaction, the insider now owns 34,809 shares of the company’s stock, valued at $8,292,896.16. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, VP Michael D. Witzeman sold 1,579 shares of Chemed stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $235.00, for a total transaction of $371,065.00. Following the completion of the transaction, the vice president now owns 4,334 shares of the company’s stock, valued at approximately $1,018,490. The disclosure for this sale can be found here. In the last three months, insiders sold 15,529 shares of company stock valued at $3,741,746. Insiders own 4.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Chemed (CHE) Updates FY18 Earnings Guidance” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/chemed-che-updates-fy18-earnings-guidance.html.

Chemed Company Profile

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply